HAVCR2 and COVID-19: Namely, we found an enrichment of two COVID-19-unique inhibitory interactions between APCs and CD8+ T cells, CTLA4/CD86 and HAVCR2/LGALS9, which may be out of necessity to curb the heightened inflammation present in severe COVID-19 (Figure 3I).